Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines

Prostate

Volumn 76, Issue 7, 2016, Pages 679-690

  Heger, Zbynek ^a,b   Gumulec, Jaromir ^b,c   Cernei, Natalia ^a,b   Polanska, Hana ^b,c   Raudenska, Martina ^b,c   Masarik, Michal ^b,c   Eckschlager, Tomas ^d   Stiborova, Marie ^d   Adam, Vojtech ^a,b   Kizek, Rene ^a,b  

^a MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^b BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

cancer metabolism; dimethylglycine; folate; glycine; prostate cancer; sarcosine pathway

Indexed keywords

ASPARTIC ACID; DIMETHYLGLYCINE; GLUTAMIC ACID; GLYCINE; GLYCINE METHYLTRANSFERASE; MESSENGER RNA; SARCOSINE; SERINE; AMINO ACID;

ARTICLE; CANCER GROWTH; CELL ASSAY; CELL DIVISION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL LINE; CELL MOTION; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PROSTATE; PROSTATE TUMOR; TUMOR CELL LINE;

AMINO ACIDS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; GLYCINE N-METHYLTRANSFERASE; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; SARCOSINE;

EID: 84986286576     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23159     Document Type: Article

References (39)

1. Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2012; 61(3):549–559.
2. Lucarelli G, Fanelli M, Larocca AMV, Germinario CA, Rutigliano M, Vavallo A, Selvaggi FP, Bettocchi C, Battaglia M, Ditonno P. Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0ng/ml. Prostate 2012; 72(15):1611–1621.
3. Zitka O, Heger Z, Kominkova M, Skalickova S, Krizkova S, Adam V, Kizek R. Preconcentration based on paramagnetic microparticles for the separation of sarcosine using hydrophilic interaction liquid chromatography coupled with coulometric detection. J Sep Sci 2014; 37(5):465–475.
4. Cernei N, Heger Z, Gumulec J, Zitka O, Masarik M, Babula P, Eckschlager T, Stiborova M, Kizek R, Adam V. Sarcosine as a potential prostate cancer biomarker—A review. Int J Mol Sci 2013; 14(7):13893–13908.
5. Metallo CM. Expanding the reach of cancer metabolomics. Cancer Prev Res 2012; 5(12):1337–1340.
6. Luka Z, Pakhomova S, Loukachevitch LV, Newcomer ME, Wagner C. Differences in folate-protein interactions result in differing inhibition of native rat liver and recombinant glycine N-methyltransferase by 5-methyltetrahydrofolate. Biochim Biophys Acta 2012; 1824(2):286–291.
7. Mitchell AD, Benevenga NJ. Importance of sarcosine formation in methionine methyl carbon oxidation in rat. J Nutr 1976; 106(12):1702–1713.
8. Soriano A, Castillo R, Christov C, Andres J, Moliner V, Tunon I. Catalysis in glycine N-methyltransferase: Testing the electrostatic stabilization and compression hypothesis. Biochemistry 2006; 45(50):14917–14925.
9. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu JD, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao XH, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457(7231):910–914.
10. Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX, Yao XD. A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate 2011; 71(7):700–710.
11. Liang CC, Park AY, Guan JL. In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2(2):329–333.
12. Song YH, Shiota M, Kuroiwa K, Naito S, Oda Y. The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod Pathol 2011; 24(9):1272–1280.
13. Fu YM, Lin HM, Fang WG, Meadows GG. Cell death of prostate cancer cells by specific amino acid restriction depends on alterations of glucose metabolism. J Cell Physiol 2010; 224(2):491–500.
14. Heger Z, Cernei N, Kudr J, Gumulec J, Blazkova I, Zitka O, Eckschlager T, Stiborova M, Adam V, Kizek R. A novel insight into the cardiotoxicity of antineoplastic drug doxorubicin. Int J Mol Sci 2013; 14(11):21629–21646.
15. Fu YM, Yu ZX, Li YQ, Ge XK, Sanchez PJ, Fu X, Meadows GG. Specific amino acid dependency regulates invasiveness and viability of androgen-independent prostate cancer cells. Nutr Cancer 2003; 45(1):60–73.
16. Stachlewitz RF, Li XL, Smith S, Bunzendahl H, Graves LM, Thurman RG. Glycine inhibits growth of T lymphocytes by an IL-2-independent mechanism. J Immunol 2000; 164(1):176–182.
17. Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A, Chinnaiyan AM. The role of sarcosine metabolism in prostate cancer progression. Neoplasia 2013; 15(5):491–501.
18. Huang YC, Lee CM, Chen M, Chung MY, Chang YH, Huang WJS, Ho DMT, Pan CC, Wu TT, Yang S, Lin MW, Hsieh JT, Chen YMA. Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res 2007; 13(5):1412–1420.
19. Heger Z, Cernei N, Krizkova S, Masarik M, Kopel P, Hodek P, Zitka O, Adam V, Kizek R. Paramagnetic nanoparticles as a platform for FRET-based sarcosine picomolar detection. Sci Rep 2015; 5:1–7.
20. Bar-Peled L, Sabatini DM. Regulation of mTORC1 by amino acids. Trends Cell Biol 2014; 24(7):400–406.
21. Torrente M, Guetg A, Sass JO, Arps L, Ruckstuhl L, Camargo SMR, Verrey F. Amino acids regulate transgene expression in MDCK cells. PLoS ONE 2014; 9(5):1–13.
22. Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 2003; 83(1):183–252.
23. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012; 336(6084):1040–1044.
24. Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma SM, Soh BS, Sun LL, Tai BC, Nga ME, Bhakoo KK, Jayapal SR, Nichane M, Yu Q, Ahmed DA, Tan C, Sing WP, Tam J, Thirugananam A, Noghabi MS, Pang YH, Ang HS, Robson P, Kaldis P, Soo RA, Swarup S, Lim EH, Lim B. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012; 148(1–2):259–272.
25. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM, Brugge JS, Cantley LC, Vander MG, Heiden. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011; 43(9):869–874.
26. Wang J, Alexander P, Wu LJ, Hammer R, Cleaver O, McKnight SL. Dependence of mouse embryonic stem cells on threonine catabolism. Science 2009; 325(5939):435–439.
27. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927; 8(6):519–530.
28. Barger JF, Plas DR. Balancing biosynthesis and bioenergetics: Metabolic programs in oncogenesis. Endocr Relat Cancer 2010; 17(4):287–304.
29. Wise DR, Thompson CB. Glutamine addiction: A new therapeutic target in cancer. Trends Biochem Sci 2010; 35(8):427–433.
30. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008; 105(48):18782–18787.
31. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010; 70(3):859–862.
32. Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, Sadowski MC, Balaban S, Schreuder M, Nagarajah R, Wong JJL, Metierre C, Pinello N, Otte NJ, Lehman ML, Gleave M, Nelson CC, Bailey CG, Ritchie W, Rasko JE, Holst J. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol 2015; 236(3):278–289.
33. Amelio I, Cutruzzola F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci 2014; 39(4):191–198.
34. DeBerardinis RJ. Serine metabolism: Some tumors take the road less traveled. Cell Metab 2011; 14(3):285–286.
35. Chaneton B, Hillmann P, Zheng L, Martin ACL, Maddocks ODK, Chokkathukalam A, Coyle JE, Jankevics A, Holding FP, Vousden KH, Frezza C, O'Reilly M, Gottlieb E. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 2012; 491(7424):458–462.
36. Moreadith RW, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor-cell mitochondria—Role of mitochondrial NADP(P)+-dependent malic enzyme. J Biol Chem 1984; 259(10):6215–6221.
37. Kim KH, Rodriguez AM, Carrico PM, Melendez JA. Potential mechanisms for the inhibition of tumor cell growth by manganese superoxide dismutase. Antioxid Redox Signal 2001; 3(3):361–373.
38. Newsholme P, Lima MMR, Porcopio J, Pithon-Curi TC, Doi SQ, Bazotte RB, Curi R. Glutamine and glutamate as vital metabolites. Braz J Med Biol Res 2003; 36(2):153–163.
39. Maddocks ODK, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 2013; 493(7433):542–546.